Clinical trials located in


Bytom city is located in Poland. Currently, 12 clinical trials are being conducted in this city.

Bytom, located in Upper Silesia, Poland, is a city with a rich history dating back to the 11th century. Known for its architectural diversity, it features Gothic, Neo-Renaissance, and Modernist styles. The city was a significant mining center, with coal mining shaping its economy and landscape until the industry’s decline. Bytom is home to the Upper Silesian Museum, showcasing regional art and history, and the Silesian Opera, one of Poland’s renowned cultural institutions. Additionally, it hosts the annual Bytom Dance and Movement Festival, highlighting its cultural vibrancy.

  • CT-EU-00116193

    Efficacy and safety study of rosnilimab in moderate to severe rheumatoid arthritis

    This study will evaluate the effectiveness and safety of Rosnilimab in patients with moderate to severe rheumatoid arthritis. Rosnilimab is an antibody that activates the PD-1 receptor, also known as ANB030. Patients will be randomly assigned to receive Rosnilimab or placebo.

    The main aim of the study is to assess changes in the 28-Joint Disease Activity Index based on the concentration of C-reactive protein (DAS28-CRP) after 12 weeks of treatment. DAS28-CRP is a validated tool that assesses disease activity based on the number of painful and swollen joints and the concentration of C-reactive protein in the blood. A reduction in DAS28-CRP indicates an improvement in the patient’s condition.

    This study aims to test whether Rosnilimab is effective and safe in the treatment of rheumatoid arthritis. If the results are promising, this drug could become a new treatment option for patients suffering from this disease.

  • Evaluating SAR441566 in Adults with Moderate-to-Severe Rheumatoid Arthritis

    This clinical trial is designed to explore the effectiveness and safety of a new medication called SAR441566 in adults who are dealing with moderate-to-severe rheumatoid arthritis (RA). If you’re an adult who hasn’t found relief from RA with methotrexate alone and haven’t tried biologic or targeted synthetic disease-modifying anti-rheumatic drugs yet, this study might be of interest to you.

    The study is set up as a double-blind, placebo-controlled experiment, which means neither you nor the study team will know if you’re receiving the actual medication or a placebo. This is a key part of ensuring the results are unbiased. You’ll be randomly placed into one of five groups, with some receiving SAR441566 and others a placebo, all alongside your regular methotrexate treatment.

    The trial will last for about 149 days, including a 6-week period before the treatment starts to confirm your eligibility, a 12-week treatment phase, and a 2-week follow-up period after treatment ends to monitor your safety. Throughout the study, you’ll visit the study center 8 times.

    One of the main goals of this study is to see if participants show a significant improvement in their RA symptoms, specifically looking for a 20% improvement in the American College of Rheumatology (ACR) score by week 12. This score measures various aspects of RA, including joint tenderness and swelling, pain levels, and overall physical function.

    By participating, you’ll be contributing to research that could lead to new treatment options for RA, potentially offering relief to many who are searching for more effective therapies.

  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    AustriaBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandSlovakiaSpainUnited Kingdom
  • Testing tulisokibart’s effects on systemic sclerosis related lung disease

    This is a study about the safety and effectiveness of a drug called tulisokibart for people with a specific lung disease often seen in patients with a disease called systemic sclerosis. The lung disease makes it hard for them to breathe because their lung tissues are becoming thick and hard. In this trial, some patients will get tulisokibart and others will get a placebo (a pill without any active medicine). Everyone will be watched closely for any negative reactions, such as unwanted symptoms or health problems. To check how well the drug works, they there will be done a few tests.

    BelgiumFranceGermanyHungaryItalyNetherlandsNorwayPolandSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • A new drug trial for the treatment of lupus

    This research studies a new drug, ESK-001, for adults with systemic lupus erythematosus (SLE), a chronic autoimmune disease. The trial will compare ESK-001’s effectiveness and safety against a placebo over 48 weeks. It will involve 388 participants, randomized to receive either ESK-001 or a placebo. The main focus is to see if ESK-001 can reduce lupus symptoms and improve quality of life. Researchers will also monitor any side effects and overall safety of the drug.

    BulgariaDenmarkGermanyHungaryPolandRomaniaSpainUnited Kingdom
  • Bepirovirsen treatment for chronic hepatitis B

    This study investigates the effectiveness and safety of a new treatment, bepirovirsen, for chronic Hepatitis B in patients already taking specific antiviral drugs. Participants will be divided into groups, receiving either bepirovirsen or a placebo, followed by their usual antiviral medication. The study consists of four stages, including initial treatment, continued antiviral therapy, a phase where some may stop their antiviral drugs, and a final follow-up. The goal is to see if bepirovirsen can improve Hepatitis B outcomes compared to standard treatment alone. The study will take place over approximately 104 weeks, with eligibility criteria ensuring participants have chronic Hepatitis B and are on stable antiviral therapy.

  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

  • Effectiveness of setanaxib in primary biliary cholangitis

    This clinical trial aims to study the effectiveness of a new medication called setanaxib on patients suffering from primary biliary cholangitis (PBC), a type of liver disorder, and with elevated liver stiffness. The drug is being tested for its ability to improve patients’ health over a course of a year. Participants of the study, adults aged 18 years and older, are either not responding adequately or are intolerant to a common PBC treatment, Ursodeoxycholic acid (UDCA). The study employs a randomized double-blind method, meaning patients are randomly placed into groups and neither patients nor researchers know who gets the actual drug or a placebo. The trial will last 52 weeks with an extension phase that could last an additional year. 

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom

See more clinical trials in other cities in Poland: